Tag Archives: MEQ

Safer medical devices with Picosun’s antimicrobial ALD coatings

ESPOO, Finland, Feb. 13, 2021 — Picosun Group, the leading provider of AGILE ALD® (Atomic Layer Deposition) thin film coating technology and solutions, reports excellent aseptic properties measured from its ALD materials.

Numerous ALD oxide coatings deposited with Picosun’s processes showed remarkable reduction of microbial growth and had low values of bacterial endotoxin contamination(*). The coatings were characterized by an independent third party laboratory according to ISO 22196:2011 antimicrobial standard and ANSI/AAMI ST72:2019 bacterial endotoxin standards. These results, along with the earlier tests validating the non-cytotoxicity of Picosun’s ALD films, prove the safety and aseptic benefits of these materials in medical devices, both implanted and external ones.

Millions of people worldwide live with medical implants and the trend is towards even more complex solutions that combine highly advanced microelectronics with miniaturized devices embedded into sensitive areas of the body such as brain, spine, eyes, and heart. Protecting these devices from the corrosive environment of the human body, and vice versa, is of utmost importance considering the safety, correct operation, and lifetime of the implant.

Picosun is the trailblazer in providing medical ALD solutions to device manufacturers. Picosun’s ultra-thin, biocompatible ALD coatings guarantee hermetic encapsulation of the implanted device, with a fraction of film thickness compared to other coating methods and with superior film uniformity and conformality, ensuring pinhole-free coverage over even the smallest details of the device. Extended lifetime and operational reliability of the implant reduces the need for corrective or replacement surgeries, thus saving expensive hospital stays and improving the patient’s quality of life. For manufacturers, hermetic protective coating enables use of more common base materials, e.g. stainless steels instead of precious metals, which in turn makes the manufacturing process easier and saves costs.

"The aseptic properties of our ALD films are so excellent that they surpass even the strictest requirements of the medical implant industry. We are excited to bring our new, advanced medical ALD solutions to the market and help our customers keep spearheading their industries with safer, longer-lasting and user-friendly products," states Juhani Taskinen, Head of Medical Business Area of Picosun Group.

Picosun provides the most advanced AGILE ALD® (Atomic Layer Deposition) thin film coating solutions for global industries. Picosun’s ALD solutions enable technological leap into the future, with turn-key production processes and unmatched, pioneering expertise in the field – dating back to the invention of the technology itself. Today, PICOSUN® ALD equipment are in daily manufacturing use in numerous leading industries around the world. Picosun is based in Finland, with subsidiaries in Germany, USA, Singapore, Japan, South Korea, China mainland and Taiwan, offices in India and France, and a world-wide sales and support network. Visit www.picosun.com.

(*)The results are part of ULIMPIA project, funded by PENTA under grant number PENTA-2017-Call2-16101-ULIMPIA.

More information:
Mr. Juhani Taskinen
Head of Medical Business Area, Picosun Group
Tel: +358 50 4066 957
Email: info@picosun.com
Web: www.picosun.com
 

CONTACT:

Minna Toivola
D.Sc., Marketing Manager, Picosun Oy
Email: minna.toivola@picosun.com
Tel: +358 40 758 8748

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/picosun-oy/r/safer-medical-devices-with-picosun-s-antimicrobial-ald-coatings,c3285079

The following files are available for download:

https://mb.cision.com/Main/16058/3285079/1371655.pdf

Safer medical devices with Picosun’s antimicrobial ALD coatings

DFI Joins Hands with German ACL to Develop Substantial Business Opportunities in the Smart Medical Market

TAIPEI, Feb. 5, 2021 — DFI, a leading industrial computer manufacturer, has entered a strategic alliance with ACL, a well-known German medical IT hardware manufacturer, and will combine with DFI’s 40 years of rich experience in industrial computers. ACL has been famous in the medical personal computer market since 1995. With profound expertise in medical IT hardware for ICU/IMC and digital operating rooms, both will join hands to open up tremendous business opportunities in the smart healthcare market.

With over 25 years of "Made in Germany" quality, ACL’s rugged and durable medical computer products are widely used in 29 out of the 37 university hospitals in Germany and deployed in many well-known medical institutions in Europe. ACL also manufactures medical-related products for many world-renowned brands such as Dräger, Olympus, eSATURNUS (Sony Group), ATMOS, XION, Cascination, Zimmer Biomet, Humanscale, and HT Group. In the initial stage, DFI will support ACL in selling their medical product portfolio in America and APAC. 

"DFI and ACL, the leaders in the smart medical market, are cooperating to create smart healthcare solutions. It is hoped that these high-quality products will open up endless business opportunities and help the medical system overcome the difficult challenges brought about by an aging society," said Steven Tsai, DFI’s President.

"For seven years, we have worked together with DFI. This strategic partnership can help us to get the latest technologies from Taiwan and faster integration into our custom-made products to the medical field," said Thomas Wollesky, ACL’s CEO.

The medical and health industry is entering a critical period of digital transformation. The alliance between DFI and ACL hopes to make an effort to improve the quality of healthcare in an aging society.

About DFI

Founded in 1981, DFI is a leading global provider of high-performance computing technology across multiple embedded industries. Smart medical applications are critical to medical quality will also be a new field where DFI will bring more contributions to an aging society.

About ACL

ACL has been manufacturing specialized IT hardware solutions for medicine and hygienically critical areas such as digital operating rooms, digitalization in intensive care units, telemedicine, and mobile solutions at its headquarters in Leipzig, Germany since 1995. Faultless and durable products are both an incentive and obligation for all ACL employees.

Kingston x CSD Reveals APAC Top 10 heartwarming face mask designs

  • Over 3,100 entries received across all APAC regions for Kingston x CSD APAC Mask Design Competition as artists induce positivity through mask designs, share compelling life stories and reflections on 2020
  • Vote online now for the favourite finalist and decide who the winner will be

TAIPEI, Jan. 27, 2021 — Continuing with the credo of preserving memories, Kingston Technology, a world leader of memory products and technology solutions, today announced the top 10 finalists of the Kingston x CSD APAC Mask Design Competition. Centered around the theme of ‘There’s Strength in Memory,’ Kingston partnered with CSD, a leading brand of face masks, to call upon all creative minds to unleash the power of memories. The initiative received an overwhelming response of over 3,100 entries from design enthusiasts across all APAC regions.

Over 3,100 entries received across all APAC regions for Kingston x CSD APAC Mask Design Competition as artists induce positivity through mask designs, share compelling life stories and reflections on 2020.
Over 3,100 entries received across all APAC regions for Kingston x CSD APAC Mask Design Competition as artists induce positivity through mask designs, share compelling life stories and reflections on 2020.

The contestants comprised of APAC’s top artists and designers from various fields. ranging from product, textile, visual and multi-media designers, to illustrators, art students and professors. Their design submissions spanned a wide canvas that encapsulated their memories, concepts regarding people’s interaction, compelling and memorable life events and reflections on 2020. The judges also discovered ongoing themes of design that centered around family bonds, appreciation of nature and intimate childhood memories: Lilo Jong from Malaysia portrayed the strong bond she has with her family, while Wu Bo Yi from Taiwan found inspiration from a childhood snack; Tsuyoshi Artman, from Japan, depicted the beauty of nature to highlight the act of breathing. Despite submissions from artists with diverse backgrounds, one thing that united the contestants was the effort to represent positivity in the lives of people across regions, thus, unleashing the power of memories.

Commenting on the outstanding response, Kevin Wu, sales/marketing and business development Vice President of APAC region, Kingston, said, "Our memories are the most precious assets in our lives and we at Kingston have always strived to help our customers preserve their memories in the best way possible with our products and campaigns. Our unique partnership with CSD for the Kingston x CSD APAC Mask Design Competition, has helped us in our journey of bringing people closer with their most profound memories. We are overwhelmed to see so many contestants finding and sharing strength in their memories; their designs therefore embody deeper emotions that range from pleasant to more challenging times that they’ve encountered. Through this campaign, we are humbled to have been an intrinsic part of our contestants’ life-altering as well as inspiring moments."

Commenting on the stellar designs, Jonathan Chang, COO of CSD, said, "Over the past few years, CSD has redefined the concept of the face mask by infusing fashion elements into it. It is exhilarating to also see such innovation from the contestants. Not only have they evolved face mask into an individual canvas, but also redefined memories into a fashion statement with their brushstroke. I’m thrilled that our creative alliance with Kingston has pushed the boundaries and reinvented the notion of memory and face masks into a new form of art."

The top 10 designs were selected from over 3,100 entries, with 5 designs each under the two different judging criteria; the "3-Colors" group emphasized on creative patterns consist of only three colors, whereas the "Unlimited Colors" group stressed on how well contestants play with their colors.

The "3-Colors" Finalists:

Perfect Imperfections, Aljohn M. Matias (Philippines)
Siamese Fighting Fish, Waraporn Mamee (Thailand)
Lips & Water Chestnut, Wu Bo Yi (Taiwan)
Doodling Paper, Nguyen Dang Binh (Vietnam)
Sparkling Lenses, Rishabh Raj (India)

The"Unlimited Colors" Finalists: 

Love Memories Forever, Lilo Jong (Malaysia)
Construct X Deconstruction, Brenca Sun (Taiwan)
Summer memories in the wonder garden, Hsu, Hsing-Chen (Taiwan)
Breath of Energy, Tsuyoshi Artman (Japan)
Monster Nation, Yman.S (Malaysia)

People can now vote for their favorite designs and determine who will be the winner of the competition. Online voting starts January 27, 2021 and will end on February 7, 2021. For winner announcement for the fan-favorite awards and more details please refer to: http://kings.tn/Mask_Design_Finalists

Watch the top 10 finalists video in the pinned post here. Comment and share the video and other related social posts on Kingston’s social channels for a chance to win the exclusive Memory Box with facemasks of the top 10 designs!

Kingston can be found on:

Facebook: https://www.facebook.com/KingstonAPAC
YouTube: http://www.youtube.com/user/KingstonAPAC

Kingston – Guarding Your Memories, Kingston is With You

Kingston has consistently safeguarded people’s precious memories for 33 years with the highest quality standards. By preserving people’s memories, we have become the driving force for progressive development. Resonating our long-term values, we believe that only with "memory" growth, there can be breakthroughs in "memory" technology. Only with excellent "memory", people can become the world’s best, and as an indispensable part of their memories – ‘Kingston is With You’.

From big data, to laptops and PCs, to IoT-based devices like smart and wearable technology, to design-in and contract manufacturing, Kingston helps deliver the solutions used to live, work and play. The world’s largest PC makers and cloud-hosting companies depend on Kingston for their manufacturing needs, and our passion fuels the technology the world uses every day. We strive beyond our products to see the bigger picture, to meet the needs of our customers and offer solutions that make a difference. To learn more about how Kingston Is With You, visit Kingston.com.

CSD – Health in Style

Founded in 1947, CSD, as the leader in Taiwan for health protection supplies, we have supplied reliable and quality medical suppliers to doctors and hospitals internationally, and have become a significant player in the process. With profound changes in homecare needs over the last few decades, brought about by the likes of SARS, COVID-19, etc. CSD took their expertise and applied it to their vision for the consumer homecare market. Since 2015, CSD has created a series of fashion medical face masks, which not only deliver high levels of safety and performance, but also combines health and style to an everyday homecare product. In addition, CSD has collaborated with multiple international boutique brands, as well as special events and concerts. For decades to come, from hospitals to the street, CSD will continue to redefine standards and set new trends – ‘Health in Style’.

Kingston and the Kingston logo are registered trademarks of Kingston Technology Corporation.

Kingston and the Kingston logo are registered trademarks of Kingston Technology Corporation. IronKey is a registered trademark of Kingston Digital, Inc. All rights reserved. All trademarks are the property of their respective owners.

Related Links :

http://www.kingston.com/

Medibio Granted CE Mark Approval for MEBsleep


MINNEAPOLIS, Jan. 19, 2021Medibio Limited (MEB or the Company)(ASX: MEB)(OTCPINK: MDBIF), is pleased to announce that it has received CE Mark approval for its sleep staging software, MEBsleep.

MEBsleep is a software-only medical device that analyses Electroencephalogram (EEG) and Electrocardiogram (ECG) data collected during polysomnography to verify sleep stages and heart rate variability (HRV) in patients suffering from primary or secondary sleep disturbances. MEBsleep uses artificial intelligence, deep learning algorithms and neural network methodology to analyse large amounts of raw data, including autonomic nervous system modulation throughout sleep stages, to highlight key information to assist the physician in understanding the patient’s condition.

Currently, the gold standard for identifying sleep stages in a sleep laboratory setting is a 60 to 90 minute visual assessment conducted by a clinician. MEBsleep performs the same assessment in 60 to 90 seconds, thereby providing improved efficacy for overall patient evaluation by sleep medicine technicians, under the supervision of a physician.

CE Mark approval will allow Medibio to commercialise MEBsleep across the European Economic Community. The intended users of this device are sleep technicians and researchers. The path is now clear for Medibio to accelerate its commercialization activities for MEBsleep in the EEC. The company is currently exploring commercialization paths with European academic groups and pharma companies focused on behavioural sleep medicine.

Claude Solitario, Managing Director of Medibio, said the approval was a significant regulatory milestone.

"MEBsleep is our first marketable product with CE Mark and its approval is an important step on our path towards commercialisation. Furthermore, it is also an important validation as we advance development of our depressive burden software medical device MEB-001, of which MEBsleep is a component," said Mr Solitario.

The prevalence of sleep disorders, such as insomnia, sleep apnea, and Restless Leg Syndrome, has increased appreciably in recent years, as has general awareness of their debilitating effects. Consequently, the global market for sleep aids, which was valued at US$71billion in 2018, is forecasted to grow at a compound annual rate of 7% between 2019 and 2025[1]. Europe and North America together account for more than 65% of total sales of sleep aids globally, with the United States, Germany, and the UK among the top markets. 

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental wellbeing solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

YES Partners with Singapore’s Gaia Science

Specialists in SEA, China science & biotech equipment market to expand YES’s global reach

FREMONT, Calif., Dec. 7, 2020 — YES (Yield Engineering Systems, Inc.), a leading manufacturer of process equipment for semiconductor advanced packaging, Life Science and "More-than-Moore" applications, today announced that it has signed an agreement with Gaia Science Pte. Ltd of Singapore to sell and service YES equipment in southeast Asia and mainland China. 

The partnership, which began in early September, is expected to be particularly helpful in showcasing YES’s monolayer coating and plasma cleaning products to the region’s dynamic Life Science Industries.

"We see considerable synergy between our products and Gaia’s expertise in the areas of microfluidics, engineering polymers, genomics, 3D printing, DNA diagnostics, and oligonucleotides research. That synergy, together with both our companies’ experience in semiconductors, gives us high hopes for this new venture," said Rezwan Lateef, President of YES.

"YES products are well-accepted among the world’s leading Life Science companies, and we look forward to strengthening our relationships with these customers in our region. We see a very good fit for YES products in our portfolio. With our extensive coverage of the Life Science and physical science markets, we expect to leverage the capabilities that YES products bring to both the biotech and semiconductor sectors," said Ms Weng Lijuan, Managing Director at Gaia.

About YES

YES (Yield Engineering Systems, Inc.) is a leading manufacturer of high-tech, cost-effective equipment for transforming surfaces, materials and interfaces.  The company’s product lines include vacuum cure ovens, chemical vapor deposition (CVD) systems, and plasma etching tools used for precise surface modification and thin-film coating of semiconductor wafers, semiconductor and MEMS devices, biosensors and medical substrates. With YES, customers ranging from startups to Fortune 100 companies can create and volume-produce products in a wide range of markets, including Advanced Packaging, MEMS, Augmented Reality/Virtual Reality and Life Sciences. YES is headquartered in Fremont, California, with a growing presence globally. For more information, please visit www.yieldengineering.com.

Media Contact

Victoria Barnes
Director of Communications
YES (Yield Engineering Systems, Inc.)
510-954-6723 direct
VBarnes@yieldengineering.com

About Gaia

Based in Singapore, Gaia Science Pte. Ltd has extensive experience supplying state-of-the-art scientific and laboratory equipment to universities, research institutions and industries. The company is recognized for bringing cutting-edge technologies from its partners and principals to customers working in application areas such as genomics, proteomics, cell biology, animal research, organic synthesis, nanotechnology, clean energy research, environmental analysis, imaging, and education. Besides providing turnkey laboratory solutions to its customers, Gaia Science is also involved with international partners in the design and manufacturing of bioengineering products. For more information, please visit www.gaiascience.com.sg.

Related Links :

home

PixCell Medical to Enhance NSW Health Pathology’s Point-of-Care Testing Service

Following TGA approval, NSW Health to Implement PixCell’s HemoScreen Device Across Health System

YOKNEAM ILIT, Israel, Dec. 2, 2020 — PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, announced today that NSW Health Pathology, the provider of public pathology services for the New South Wales (NSW) government, will deploy PixCell’s HemoScreen hematology analyzer for rapid, lab-accurate Complete Blood Count (CBC) testing, accessible at the point of care.

PixCell has worked closely with NSW Health Pathology over the past year to evaluate the HemoScreen and they are now in the position to pioneer the use of this innovative POCT technology in facilities across the state.

HemoScreen will enable true point-of-care testing (POCT) in terms of operation, electronic result delivery through an Internet of Things approach, ease-of-use, and transportability, while still providing core lab quality results. Outside of Sweden and Denmark, Australia will be the first country to get HemoScreen devices, which will soon be implemented throughout NSW.

The collaboration includes the installation of a large number of HemoScreen devices that provide the full 5-part differential CBC test with comprehensive abnormal cell flagging. In this initial deployment, NSW Health Pathology will implement HemoScreen devices within small labs, in large emergency departments without onsite labs, and to upgrade some existing technology. The devices will then be further assessed for utility in oncology clinics and other settings.

"We recognize the need to simplify real-time blood testing and are proud to work with NSW Health Pathology to increase accessibility to POC diagnostics," said Avishay Bransky, Ph.D., CEO and co-founder of PixCell Medical. "HemoScreen delivers accurate readings of 20 standard blood count parameters, which are routinely used to check the overall health status of a patient. The CBC has recently found valid to monitor the severity of COVID-19 and the progression of the disease."

POCD Scientific, boasting over 125 years of experience in the supply and use of scientific equipment and products, will be the sole distributor of HemoScreens for the region of Australia.

This news follows PixCell’s recent approval from the TGA.

About PixCell Medical

PixCell Medical provides the first truly portable point-of-care blood diagnostic solution. Leveraging the company’s patented Viscoelastic Focusing technology, along with AI-powered machine vision, PixCell’s FDA-cleared and CE-approved HemoScreen diagnostic platform shortens diagnostic results delivery from days to minutes. With just one drop of blood and within six minutes, PixCell delivers accurate readings of 20 standard blood count parameters, saving patients, clinicians and health systems significant time and costs.

For more information: www.pixcell-medical.com and follow PixCell on LinkedIn.

Media Contact:
Finn Partners for PixCell Medical
Lior Feigin
lior.feigin@finnpartners.com
@LiorFeigin

Re-Innovation of Thermal Imaging Technology – FOTRIC Releases Intelligent Thermal Imagers 340A & 340M

SHANGHAI, Dec. 1, 2020 — Professional thermal imaging brand FOTRIC continues to innovate in technology for users to "enhance efficiency and ensure safety". In August, FOTRIC launched a temperature screening thermal imager for epidemic prevention and maintenance control. Recently, FOTRIC released a breakthrough: intelligent thermal imagers 340A and 340M, which are suitable for industrial equipment maintenance, power and electrical testing, building inspection, etc.

Looking back, FOTRIC has repeatedly achieved successes in product development. In 2017, FOTRIC participated in the USA CES Exhibition and its independently developed products were widely acclaimed. In 2018, FOTRIC won the first place in the electrical application category in the USA IR/INFO Conference. In 2019, FOTRIC’s newly developed product won the 2019 German iF International Industrial Design Award.

AI Boosted Performance

Industrial users are familiar with thermal imagers. However, 340A and 340M are not ordinary models. FOTRIC innovatively fuses AI technology with wisdom and agile genes and brings users an extraordinary intelligent control experience. For example, there is an AI Key supporting programming shortcuts to preset interfaces or functions.


Superior Imaging

"Temperature measurement" and "imaging" are the two core functions of the thermal imager. An easy-to-use thermal imager is inseparable from accurate temperature measurement and high-definition imaging. 340A and 340M are developed based on FOTRIC’s ten years’ solid technology focusing on accurate temperature measurement and thermal imaging. Their temperature measurement stability and consistency have reached the industry-leading level. For imaging, FOTRIC brings a breakthrough innovative technology – "MagicThermal" Multi-color Dynamic. This function allows advanced imaging performance under complex diagnoses and superior in-picture smart isolation of hot-spots for easy live analysis of areas of interest.


TurboFocus on the Go

The 340A model is equipped with an intelligent focusing system "TurboFocus", which realizes fast, accurate, and quiet one-button autofocus. While with the continuous focus function, users do not need to concern about focusing, and can just aim and shoot, which greatly improves the detection efficiency.

At present, FOTRIC seeks partners worldwide to provide local users with customized high-quality services.

About FOTRIC

FOTRIC is the world’s leading provider of precision temperature measurement infrared thermal imaging products and solutions.

Headquartered in Shanghai, China, FOTRIC has distributors in tens of countries and regions including North America, Europe, South Korea, Singapore, Australia, and Taiwan. FOTRIC’s sales network covers multiple fields including power, industry, scientific research, and security.

CONTACT: Celine, nsn@fotric.cn, www.fotric.com 

Related Links :

http://www.fotric.com

Asian Power Devices: Powering modern technology in an ever-shifting landscape

TAIPEI, Nov. 20, 2020 Medical field is a critical market for power supplies  APD introduces customized power supply solutions for medical equipment and network equipment. Its systems meet all EMI, temperature, peak load requirements, and company’s Medical Power Supplies protect the PSU from failure resulting from high-frequency 4G/5G signal interference.

APD Medical Power Supply & Lithium-ion UPS Solutions -- Built for the challenges of today
APD Medical Power Supply & Lithium-ion UPS Solutions — Built for the challenges of today

APD Solutions — Built for the challenges of today

This year’s pandemic challenges the current world economic situation and people’s living conditions. Working from home, online meetings, and distance learning has become the new normal. It not only increases the demand for more connected devices and network equipment, but also requires reliable power delivery.

Impact of COVID-19 on healthcare is immediate. Ventilators, oxygen concentrators, and respiratory humidifiers require a lasting, uninterrupted, and stable power supply.

The pandemic is challenging the existing power systems hospitals have relied on. Many healthcare facilities are already at, or beyond maximum capacity, the higher number of patients means more devices and medical systems on the grid.

The toll goes beyond the hospital. Manufacturers are dealing with labor shortages while medical equipment demand has increased. Many factories are speeding up automation, with a growing need for reliable power systems.

Stable and continuous power is paramount for mission-critical medical systems

Corresponds to the products for top-notch care. APD developed dedicated lithium-ion (Li-ion) UPS products to replace the traditional UPS system using lead-acid batteries, bringing multiple benefits for healthcare applications.

Li-ion battery UPS systems have twice the energy density, double the life span, and are smaller and lighter than lead-acid battery-based systems. They offer a significant reduction in maintenance and replacement costs. In the past few years, the technology’s price has dropped substantially. APD’s lithium-ion UPS products use only premium quality protection components that comply with rigorous standards.

Since 1994, Asian Power Devices (APD), with world-class R&D capabilities, highly competitive products and services, has led the power supply market. Current products include power supplies, UPS, and photovoltaic inverters. 

About APD:

When performance and reliability matter, Asian Power Devices is a reliable partner in developing solutions for the medical field. Backed by many years of experience in the industry and insight into market demands, APD provides the most complete power solutions based on customers’ special requirements, and satisfying the diversity & high safety standards of power devices. In short, when performance matters, choose APD.

For more detailed information, please visit the official website: https://www.apd.com.tw/en

Related Links :

首頁

Integrating Fitbit Wearable Devices into Diabetes Care Leads to Significant Improvements in Blood Glucose and HbA1C, Finds Health2Sync Clinical Study in Taiwan

  • Wearing Fitbit devices with Health2Sync glucose control app clinically proven to help both users and healthcare providers to control and better manage the symptoms of Type 2 diabetes
  • Results from the study in Taiwan revealed an improvement in patients’ health conditions, with participants recording higher levels of physical activity, reduced HbA1C, fasting blood glucose and LDL-C, and higher blood glucose measurement frequency
  • The Health2Sync Patient Management Platform allows healthcare providers to seamlessly monitor patients’ information and provide remote consultative advice where necessary

SINGAPORE, Nov. 13, 2020 — Health2Sync, the number one diabetes management app in Taiwan and Japan, today announced the results of their clinical study in Taiwan, demonstrating that combining Fitbit wearable devices with their Health2Sync Patient Management Platform can help users control and better manage the symptoms of Type 2 diabetes mellitus (T2DM). In the study[1], conducted with four of Taiwan’s leading diabetes clinics, participants recorded significant average improvements in key indicators, such as reduced HbA1C, fasting blood glucose  and LDL-C, and higher blood glucose measurement frequency — a valuable proof of concept for using Fitbit wearables with diabetes care protocols and solutions.     

Voluntarily connecting their Fitbit Inspire HR with the Health2Sync App enabled study participants to let their doctors seamlessly monitor their information on the Health2Sync Patient Management Platform and provide remote consultative advice where necessary.
Voluntarily connecting their Fitbit Inspire HR with the Health2Sync App enabled study participants to let their doctors seamlessly monitor their information on the Health2Sync Patient Management Platform and provide remote consultative advice where necessary.

The study found:

  • Average glycated haemoglobin (HbA1C) decreased 0.33%, while patients who did moderate to high-intensity activity duration of at least 150 mins per week, saw their average HbA1C[2] decrease 0.66%
  • Average fasting blood glucose (BG) decreased 10.92 mg/dL
  • Average low-density lipoprotein cholesterol (LDL-C) decreased 11.55 mg/dL
  • Weight reduction of up to 2 kilograms among some patients
  • Increased frequency in moderate to high intensity activity to 7.03 times a week among some patients

Conducted over a three-month period ending in July 2020 in conjunction with the Neng-Chun Diabetes Clinic, Da-Ya Chang-An Clinic, Yier Clinic and Banqiao Da-Jun Clinic, the study, with patient consent, lets the patients’ doctors track the progress and lifestyle changes of 95 participants with T2DM. Prior to the commencement of the study, doctors at the four clinics established benchmarks for all participating patients based on blood glucose tests at the start of the trial, then on a self-monitored weekly basis throughout the study period.

Each participant was given a Fitbit Inspire HR and the participants voluntarily agreed to connect their Fitbit wearable data with the Health2Sync diabetes management app to track their progress throughout the program. Physical activity data generated from each person’s Fitbit device was integrated into the Health2Sync app, which housed other health metrics such as patients’ HbA1c, BG and cholesterol levels. This let doctors seamlessly monitor patients’ information on the Health2Sync Patient Management Platform and provide remote consultative advice where necessary.

Dr. Kuo-Liang Lu of Da-Ya Chang-An Clinic in Taiwan, said: "The results speak for themselves. We saw a reduction in some of our patients’ weight by an average of two kilograms and fasting BG levels of study participants from Da-Ya Chang-An clinic decreased 11.10 mg/dL within 3 months[3], leading to significant health improvements."

Dr. Neng-Chu Yu of Neng-Chun Diabetes Clinic said: "Type 2 diabetes, with the right lifestyle changes – medication adherence, increased activity, and better diet – can lead to major improvements in control of blood glucose levels. The integration of Fitbit data with Health2Sync let me easily view my patients’ activities and self-monitored data, enabling me to make necessary suggestions and give guidance to help patients for further improvement."

Diabetes is a chronic condition that, if not managed, can lead to health complications like blindness, kidney failure, heart attacks, stroke and lower limb amputation.[4] It remains the second highest cause in premature mortality, after cancer, among major non-communicable diseases in Taiwan[5] and its prevalence has posed economic burdens such as increased personal and healthcare spending and loss of work productivity.[6]

A holistic approach to managing T2DM requires lifestyle changes, which includes medication adherence, exercise and proper diet. The integration with Fitbit wearable devices and activity data is key to helping to promote healthier behaviours and improve participants’ health outcomes. Participants received reminders for weekly exercises via their Health2Sync App, which promoted an increased frequency in moderate to high intensity activity at 7.03 times a week. The increased levels of activity corresponded with an improvement in patients’ health conditions.

"We are thrilled to see such optimistic results in the clinical study. We believe that innovations in Fitbit wearable devices and Fitbit health solutions have a major role to play in the global effort against diabetes – whether it is in reducing the onset of diabetes, or helping patients to better manage their condition – and we look forward to further expanding on our partnership with Fitbit," said Ed Deng, CEO at Health2Sync.

"The behavioural changes exhibited by study participants reinforces our belief that Fitbit amplifies our intrinsic motivation to adopt healthier habits, which can make all the difference when dealing with a condition like Type 2 diabetes where lifestyle factors play such a big role," said Steve Morley, Vice President of International Health Solutions & General Manager of Asia Pacific at Fitbit. "Together with the seamless experience that Health2Sync provides for patients and their health providers to track key indicators, they create a powerful solution that makes it simpler and more convenient to manage conditions like Type 2 diabetes."

In September last year, Fitbit and Health2Sync collaborated to allow the integration of Fitbit’s health, sleep and fitness wearable data with the Health2Sync app (with user consent) to support Health2Sync’s 520,000 users in Japan and Taiwan to better manage their conditions, like Type 2 diabetes. The new platform gives users who have a Fitbit account access to an in-app dashboard that includes the option to agree to share their wearable data from their Fitbit devices[7], including heart rate, sleep and physical activity, alongside recent blood glucose readings from Health2Sync depicting if levels fall within, above, or below the healthy range.

[1] The study was conducted on 95 participants, ages 18- 60.

[2] The term HbA1c refers to glycated haemoglobin. Diabetics with higher levels of HbA1c face greater risk of developing diabetes-related complications.

[3] Average fasting blood glucose levels of study participants from Da-Ya Chang-An clinic decreased 11.10 mg/dL compared to the study average of 10.92 mg/dL

[4] "Diabetes" World Health Organization, 2020. https://www.who.int/news-room/fact-sheets/detail/diabetes.

[5] IC Chen., Yu NC. "A Decade of Diabetes Care in Taiwan." Diabetes research and clinical practice. U.S. National Library of Medicine, 2014. https://pubmed.ncbi.nlm.nih.gov/25550058/.

[6] Wong LC., Tsai CY., Chou HK., Tsai MT., Tsai WH., Chou.P., and Shen ST. "Healthcare costs associated with progressive diabetic retinopathy among National Health Insurance enrollees in Taiwan, 2000-2004." BMC Health Services Research, May 26, 2010. https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-10-136

[7] Includes Fitbit Sense, Fitbit Versa 3, Fitbit Charge 4, Fitbit Inspire 2, among others.

About Health2Sync

Health2Sync scales diabetes care by providing a digital engagement platform that is comprised of a mobile App for diabetics, cloud-based analytics, and cloud platform for healthcare providers. The smart analytics algorithms provide users with personalized education and guidance based on their biometric and behavior data captured. With the cloud platform, healthcare providers can easily take control of patients’ condition through the analyzed data.

Health2Sync is the largest diabetes management platform in Asia (excl. China) and proven to help users improve their outcome.  Health2Sync has supported partners including pharmaceuticals, private payers, and the public payor to provide diabetics with innovative services.  In 2017, 2018 and 2019 Health2Sync was selected as Top 10 Diabetes App globally by Healthline.

QYNAPSE (France) and TRUE POSITIVE MEDICAL DEVICES (Canada) are partnering to provide the most advanced AI platform for brain diseases


Strategic partnership in brain imaging and AI

PARIS, MONTREAL, and QUEBEC CITY, Oct. 13, 2020

  • Acquisition of TRUE POSITIVE MEDICAL DEVICES by QYNAPSE
  • A strategic collaboration that covers 15 patents, including 9 issued in the U.S. and Canada
  • A unique technology alliance to improve clinical trials performance and personalize brain diseases management

QYNAPSE SAS, a French medical technology company, today announces the acquisition of the Canadian company TRUE POSITIVE MEDICAL DEVICES Inc. (TPMD), a spin-off from the universities of McGill and Laval. The objective of this strategic collaboration is to combine TPMD’s technologies, patents and expertise with Qynapse’s know-how and product line – and thus form the most advanced artificial intelligence (AI) platform in the field of imaging of brain diseases such as Alzheimer’s, Parkinson’s and multiple sclerosis.

The QyScore application
The QyScore application

Over the past fifteen years, the founders of TPMD, Prof. Louis Collins (McGill University, Montreal, Canada) and Prof. Simon Duchesne (Université Laval, Quebec City, Canada) have established one of the most impressive scientific and technological asset bases in brain imaging and AI applied to this field, supported by more than 500 publications and scientific communications. These technologies are already being used in Canada by leading research consortia and private international players in studies specifically related to neurodegeneration, such as Alzheimer’s disease.

QYNAPSE is already marketing its first QyScore® medical device to clinical centers in Europe and the United States. Its platform is also used in clinical trials involving dozens of centers worldwide. The collaboration with TPMD will allow QYNAPSE to extend the applications of its QyScore® software to other brain diseases such as stroke, epilepsy, autism, schizophrenia, and head trauma – and also to develop new software to predict clinical progression for individual patients and optimize enrollment in clinical trials.

QYNAPSE’s acquisition of TPMD covers 15 patents, including 9 issued in the United States and Canada, grouped into nine technological asset families. The founders of TPMD will join QYNAPSE’s scientific board, setting the stage for a long-term collaboration.

According to Prof. Louis Collins: "QYNAPSE is a very promising partner for TPMD and both McGill and Laval universities, which will allow us to accelerate the regulatory approval and marketing of the technologies we have developed in recent years". Prof. Duchesne adds, "Indeed, with QYNAPSE we will have access to a partner that is already well established in the medical field. We look forward to providing clinicians with the tools they need to improve the accuracy of their diagnosis, facilitate prognosis and guide treatment for diseases such as dementias and cerebrovascular diseases."

"We are delighted to partner with two of the world’s leading experts in brain imaging, and to expand our scientific and clinical collaborations with two major centers of excellence in this field." said Olivier Courrèges, CEO of QYNAPSE. "This collaboration will create a unique technological structure, strengthening our ability to deploy powerful tools to address two major challenges: clinical trial performance and personalized management of brain diseases, which affect more than one in six people worldwide."

Once finalized, TPMD will be integrated into QYNAPSE CANADA Inc. and TPMD’s scientific and commercial partnership contracts will be operated by this new entity.

About QYNAPSE

Founded in 2015, QYNAPSE is a French medical technology company, a spin-off from the CATI consortium of neuroimaging research laboratories. The company develops and markets solutions utilizing the potential of quantitative imaging and artificial intelligence to optimize diagnosis, prognosis and monitoring of patients with neurological diseases.
QYNAPSE is headquartered in Paris (France) and in Boston (USA).
www.qynapse.com 
www.qynapse.com/qyscore-software/ 

About TRUE POSITIVE MEDICAL DEVICES (TPMD)

Founded in 2011, TRUE POSITIVE MEDICAL DEVICE Inc. is a spin-off from the work of Prof. Simon Duchesne at the CERVO Brain Research Center and Université Laval and Prof. Louis Collins at the Montreal Neurological Institute and McGill University. The company designs, validates and operates a brain image processing platform to aid in the diagnosis and prognosis of neurological and psychiatric diseases.
TPMD is based in Montreal and Quebec City (QC, Canada).
www.truepositivemd.com  

Logo – https://techent.tv/wp-content/uploads/2020/10/qynapse-france-and-true-positive-medical-devices-canada-are-partnering-to-provide-the-most-advanced-ai-platform-for-brain-diseases-2.jpg
Photo – https://techent.tv/wp-content/uploads/2020/10/qynapse-france-and-true-positive-medical-devices-canada-are-partnering-to-provide-the-most-advanced-ai-platform-for-brain-diseases.jpg

Media Contact
Ysé Sallé de Chou
Qynapse
ysalledechou@qynapse.com